Bill · S. 2620· Senate(119-S-2620)
REMEDY Act
- Introduced
- 7/31/2025
- Last activity
- 7/31/2025 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000)
- Sponsored by
- Richard Durbin
- Cosponsors
- - 0 - 1
- Introduced
- In Committee
What this bill would do
The REMEDY Act seeks to amend the Federal Food, Drug, and Cosmetic Act regarding the approval of abbreviated new drug applications. The bill introduces the concept of a "covered patent" for drugs approved on or after the date of enactment. Under this rule, when a holder files information regarding specific patents, they must select one patent to serve as the "covered patent." This selected patent cannot be changed or amended once chosen. The amendment updates how patent infringement actions and the thirty-month period are handled for these specific patents.
Yes
Does this lower the price of prescription medicines?+4
By restricting patent 'evergreening' tactics, the bill aims to allow generic competitors to enter the market more predictably.
Would households on low incomes be better off under this?+3
Lowering drug prices through patent reform benefits those with limited purchasing power.
Does this make it easier to run a small business?+2
The bill may facilitate generic drug competition by limiting the ability of brand-name holders to manipulate patent timelines.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
- Standardization of Patent Selection: By requiring a holder to select one patent as a "covered patent" and prohibiting changes to that selection (Section 2, subsection (c)(2)), the bill creates a specific, fixed patent that governs the thirty-month period and infringement actions.
Potential Negative Impacts for People
- Restrictions on Patent Flexibility: For drugs approved on or after the enactment of this act, the holder is required to select a single "covered patent" which "may not be changed or amended" (Section 2, subsection (c)(2)). This limits the ability of a patent holder to adjust which patent is used for the thirty-month period or associated legal actions.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Healthcare
- Reduces Prescription Drug Costs+4
- Demographic And Interest Groups
- Good For Low Income Households+3
- Economy And Finance
- Improves Small Business Support+2
- 7/31/2025
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000)
- 1 Cosponsor added.
- Introduced in Senate
Bill CassidyRepublican · Louisiana